RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020

Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Human vaccines & immunotherapeutics 2022-11, Vol.18 (6), p.2140533
Hauptverfasser:	Packnett, Elizabeth R., Winer, Isabelle H., Larkin, Heather, Oladapo, Abiola, Gonzales, Tara, Wojdyla, Matthew, Goldstein, Mitchell, Smith, Vincent C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Child Gestational Age Hospitalization Humans Immunotherapeutics Infant Infant, Newborn Infant, Premature Infant, Premature, Diseases - prevention & control Palivizumab - therapeutic use pediatric hospitalization pre-exposure prophylaxis premature Respiratory syncytial virus Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus, Human respiratory tract infections United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions and those born at
ISSN:	2164-5515 2164-554X 2164-554X
DOI:	10.1080/21645515.2022.2140533